Nadolol

Information about Nadolol

Nadolol is a nonselective beta-adrenergic receptor blocker that is widely used for the therapy of hypertension, angina pectoris and vascular headaches.

Liver safety of Nadolol

Nadolol has yet to be convincingly associated with clinically apparent liver injury.

Mechanism of action of Nadolol

Nadolol (nay' doe lol) was the second beta-blocker developed for therapy of hypertension and is considered nonselective, acting on both the beta-1 and beta-2 adrenergic receptors. Beta-1 adrenergic blockade reduces the heart rate and myocardial contractility by slowing the atrioventricular (AV) conduction and suppressing automaticity. Beta-2 blockade affects peripheral vascular resistance and can cause bronchospasm and hypoglycemia. The beta-2 blockade is responsible for the majority of adverse effects associated with nadolol.

FDA approval information for Nadolol

Nadolol was approved for use in the United States in 1979 and is still commonly used, with more than 1 million prescriptions filled yearly. Nadolol is indicated for the management of hypertension and angina pectoris, and is used off label for prophylaxis against migraine and vascular headaches.

Dosage and administration for Nadolol

Nadolol is available in multiple generic forms and under the trade name of Corgard in tablets of 20, 40, 80, 120 and 160 mg. Fixed combinations with diuretics are also available (nadolol and bendroflumethiazide: Corzide). The typical dose of nadolol in adults is 40 to 80 mg once daily.

Side effects of Nadolol

Common side effects of nadolol include bradycardia, hypotension, fatigue, dizziness, depression, memory loss, incontinence, cold limbs and, less commonly, severe hypotension, heart failure and bronchospasm. Sudden withdrawal can trigger rebound hypertension. Beta-blockers are contraindicated in patients with asthma, bradycardia and heart failure, and should be used cautiously in the elderly and in patients with diabetes.

Antihypertensive agents

• Dailymed label info on Nadolol
• FDA Nadolol

Nadolol Resources
Latest articles Most recent articles Ongoing trials	Wikipedia